Committee(s):	Dated:
City of London Health & Wellbeing Board	05 July 2024
Subject:	Public
Presentation from Dr Matt Liveras	
Which outcomes in the City Corporation's Corporate	n/a
Plan does this proposal aim to impact directly?	
Does this proposal require extra revenue and/or	N
capital spending?	
If so, how much?	n/a
What is the source of Funding?	n/a
Has this Funding Source been agreed with the	n/a
Chamberlain's Department?	
Report of: Dr Matt Liveras, Consultant Psychiatrist and	For Information
Medical Lead, Klearwell	
Report author: As above	

# Summary

Dr Liveras comes at the invitation of Health & Wellbeing Board to present on the effects of ketamine-assisted therapy.

# Recommendation(s)

• Members are asked to note the report.

# Main Report

# Background

The presentation (appendix 1) sets out some of the background to the use of ketamine in therapy and current uses.

# **Current Position**

N/A

# Options

N/A

# Proposals

N/A

# Key Data

N/A

# Corporate & Strategic Implications – [*Please state 'none' if not applicable instead of deleting any of the sub-headings below*]

N/A

# Conclusion

N/A

# Appendices

Appendix 1 – Slide deck: <u>Ketamine-assisted therapy at Klearwell</u>

# **Emmanuel Ross**

Programme & Projects Officer, City & Hackney Public Health Service

E: emmanuel.ross@cityoflondon.gov.uk